Key result
Chitosan-conjugated cilostazol nanoparticles increase drug solubility and release.
Why the study?
Cilostazol has low solubility, high permeability, and poor bioavailability, creating a need for techniques to increase its solubility.
Formulating cilostazol as chitosan-conjugated nanoparticles successfully improves its in vitro solubility and drug release, potentially addressing its poor bioavailability.
Answers are grounded in this paper and cite their sources.
May address cilostazol bioavailability; hypothesis-generating from Level 5 animal data, clinical trials needed.
At the time of tissue injury, platelets have a major role in maintaining hemostasis and stopping the blood loss. For treating cardiovascular diseases and peripheral arterial disease, platelet aggregation inhibitors are widely used. FDA-approved drugs like clopidogrel and cilostazol were commonly used in the treatment of platelet aggregation, peripheral arterial disease, and intermittent claudication. Cilostazol is a BCS class Ⅱ drug with low solubility and high permeability. Thus, cilostazol has poor bioavailability, and a technique for increasing bioavailability is required. The aim of the present study was to increase its solubility. Nanoparticles were prepared by conjugating the cilostazol with chitosan. Cilostazol nanoparticles are prepared by using chitosan, acetic acid, DMSO, and STTP. The prepared nanoparticles were evaluated using a zeta sizer and SEM. The compatibility of cilostazol with chitosan is identified by FT-IR. Cilostazol nanoparticles increased the solubility and drug release.
No takes yet. Share an insight, caveat, or question.
Shubha et al. (2026) studied this question. Cilostazol nanoparticles was evaluated on Solubility and drug release. Cilostazol nanoparticles prepared by conjugating the drug with chitosan increased its solubility and drug release.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: